• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 27, 2011

View Archived Issues

Aegerion Adds $50M Ahead of Lomitapide NDA in HoFH

On a call with investors earlier this month, Aegerion Pharmaceuticals Inc.'s CEO, Marc Beer, said the firm was "in filing mode now," with plans to submit a new drug application for lomitapide in homozygous familial hypercholesterolemia (HoFH) by the end of this year. Read More

Will Patent Reform Make the Backlog Even Worse?

WASHINGTON – When it comes to patent reform, the cure may not treat the bite of a growing backlog of patent applications – about 700,000 at last count. Read More

Genmab Shares Slide as It Shelves Zalutumumab

Shares in Genmab A/S dropped 11 percent Friday on news that the company had failed to secure a deal for its epidermal growth factor receptor (EGFR) inhibitor zalutumumab and has opted to shelve the program. Read More

Stock Movers

Read More

EMA Issues Negative Opinion for AMT's Gene Therapy

LONDON – The European Medicines Agency (EMA) has knocked back Amsterdam Molecular Therapeutics NV's (AMT) Glybera, leaving the winning post in the race to be the first approved gene therapy in a registered market still some distance away. Read More

More Data Show Brown Fat Could be Diabetes Fighter

When scientists and clinicians meet this week in San Diego at the 71st scientific sessions of the American Diabetes Association, they have their work cut out for them: As the global population gets older and fatter overall, diabetes cases are increasing at an alarming rate. Read More

Other News To Note

ViroPharma Inc., of Exton, Pa., said the European Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of a pediatric use marketing authorization application for Buccolam (midazolam, oromucosal solution) for treating prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents. Read More

Clinic Roundup

PCI Biotech Holding ASA, of Oslo, Norway, reported results from a Phase I/II study of combination product PC-A11, which combines the photosensitizer Amphinex with the cytotoxic agent bleomycin. The drug was well tolerated, and a dose-limiting toxicity of skin photosensitivity and ulceration occurred at the fourth dose level. Complete clinical regression of target tumors was seen in 14 of 16 patients completing the first assessment and eight of 11 patients completing the second assessment. Read More

Bench Press

By connecting the eye's light-sensing machinery to cellular gene expression machinery, scientists from the Swiss Eidgenoessische Technische Hochschule in Zurich, Switzerland, have managed to use external light to switch on individual genes in a cell. Read More

BIO International Convention to Live up to Its 'Middle Name'

WASHINGTON – International will be front and center at this year's BIO International Convention taking place this week in Washington – both in who's coming and in what's being discussed. Read More

Pain Therapeutics, Durect Drop 30%+ After Remoxy CRL

Pfizer Inc. partners Pain Therapeutics Inc. and Durect Corp. shared the pain of an FDA complete response letter (CRL) on Pfizer's resubmission of the new drug application (NDA) for Remoxy (oxycodone) extended-release capsules CII. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe